Compositions and methods for treating inflammatory conditions of the bowel

• US 8,293,776 B2
• Filed: 08/05/2009
• Issued: 10/23/2012
• Est. Priority Date: 08/05/2008
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Teitelbaum, Daniel H., Showalter, Hollis, Larsen, Scott, Lucas, Peter, Koga, Hiroyuki
• Primary Examiner(s): Hui, San-Ming
• Application Number:
  US12/536,390
• Publication Number:
  US 20100035852A1
• Time in Patent Office: 1,175 Days
• Field of Search: 514381-384
• US Class Current: 514/381
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: G01N 2500/02 Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
• CPC Class Codes: G01N 33/566 using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Abstract

The present invention provides compositions and methods for treating inflammatory conditions (e.g., of the bowel). In particular, the present invention provides methods of treating (e.g., therapeutically and/or prophylactically treating) inflammatory conditions (e.g., of the bowel), compositions useful for such methods (e.g., antagonists and/or inhibitors of angiotensin II (AngII) receptor Type 1a (AT1a)), and methods of identifying, characterizing and/or optimizing such compositions. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine) and research applications.

Claims

1. A method of treating a subject, comprising:

a) providing;

i) a subject with inflammatory bowel disease, and

ii) a composition comprising an angiotensin II (AngII) receptor Type 1a (AT1a) antagonist selected from the group consisting of

2. The method of claim 1, wherein said composition comprising an AT1a antagonist is suspended in polyethylene glycol.

3. The method of claim 1, wherein said composition comprising an AT1a antagonist further comprises a corticosteroid.

4. The method of claim 1, wherein said composition comprising an AT1a antagonist is enterally administered.

5. The method of claim 4, wherein administering enterally comprises rectal administration.

6. The method of claim 5, wherein said rectal administration comprises an enema.

7. The method of claim 4, wherein administering enterally comprises oral administration.

8. The method of claim 1, wherein said inflammatory bowel disease is selected from the group consisting of Crohn'"'"'s disease, celiac disease, ulcerative colitis, diverticulitis, pouchitis, or chronic diarrhea.

9. The method of claim 1, wherein reduction of the severity of inflammatory bowel disease in said subject is detectable by a decrease in the clinical severity of colitis in said subject.

10. The method of claim 1, wherein reduction of the severity of inflammatory bowel disease in said subject is detectable by a reduction in histologic score in said subject.